Tytuł artykułu
Wybrane pełne teksty z tego czasopisma
Identyfikatory
Warianty tytułu
Języki publikacji
Abstrakty
A stability-indicating LC assay method was developed and validated for the quantitative determination of doripenem and biapenem in pharmaceutical dosage forms in the presence of degradation products formed during forced degradation studies. An isocratic RP-HPLC method was developed with a C-18 (250 mm × 4.6 mm, 5 μm) column and 12 mM ammonium acetate-acetonitrile (96:4 υ/υ) as mobile phase. The flow rate of the mobile phase was 1.0 mL min-1 for doripenem and biapenem. The determination was carried out at the wavelength of 295 nm. The carbapenems were subjected to stress conditions of degradation in aqueous solutions including hydrolysis, oxidation, photolysis, and thermal degradation. The developed method was validated with respect to linearity, accuracy, precision, selectivity, and robustness.
Słowa kluczowe
Czasopismo
Rocznik
Tom
Strony
207--219
Opis fizyczny
Bibliogr. 23 poz., rys., tab.
Twórcy
autor
- Poznan University of Medical Sciences Department of Pharmaceutical Chemistry, Faculty of Pharmacy Grunwaldzka 6 60-780 Poznań Poland
autor
- PozLab Contract Research Organization Poznań Poland
autor
- Poznan University of Medical Sciences Department of Pharmaceutical Chemistry, Faculty of Pharmacy Grunwaldzka 6 60-780 Poznań Poland
autor
- Tanaka Laboratory in Hokkaido University W 7, Kita-ku Sapporo 060-8638 Japan
autor
- Poznan University of Medical Sciences Department of Pharmaceutical Chemistry, Faculty of Pharmacy Grunwaldzka 6 60-780 Poznań Poland
Bibliografia
- [1] M. Hikida, M. Mori, and T. Kitta, Chemotherapy, 42, 101 (1994)
- [2] R.N. Jones, H.S. Sader, and T.H. Fritsche, Diagn. Microbiol. Infect. Dis., 52, 71 (2005)
- [3] H.M. Wexler, A.E. Engel, D. Glass, and C. Li, Antimicrob. Agents Chemother., 49, 4413 (2005)
- [4] C.M. Perry and T. Ibbotson, Drugs, 15, 2221 (2002)
- [5] F. Walsh, Ther. Clin. Risk Manag., 3, 789 (2007)
- [6] K. Ikawa, N. Morikawa, K. Ikeda, H. Ohge, and T. Sueda, Chemotherapy, 54, 386 (2008)
- [7] J. Patel and S.E. Cook, Am. J. Health Syst. Pharm., 54, 412 (1997)
- [8] R. Mendez, T. Alemany, and J.M. Villacorta, Chem. Pharm. Bull., 39, 831 (1991)
- [9] M. Zając, J. Cielecka-Piontek, and A. Jelińska, J. Pharm. Biomed. Anal., 43, 445 (2007)
- [10] J. Cielecka-Piontek, M. Zając, and A. Jelińska, J. Pharm. Biomed. Anal., 46, 52 (2008)
- [11] A. Mendez, J. Dalomo, M. Steppe, and E. Schapoval, J. Pharm. Biomed. Anal., 41, 1363 (2006)
- [12] Kayo, I. Kazuro, I. Aki, N. Yoshimi, M. Norifumi, J. Chromatogr. B, 844, 148 (2006)
- [13] Kayo, I. Kazuro, M. Norifumi, K. Keiko, U. Nami, O. Hiroki, and S. Taijiro, J. Chromatogr. B, 867, 20 (2008)
- [14] P.A. Psathas, K. Kuzmission, and S.Y. Ikeda, Clin. Ther., 30, 2075 (2008)
- [15] X. Ming, H. Tai-Jun, Z. Fei, L. Xiao-Min, and X. Xiang-Yang, J. Biomed. Pharm. Anal., 49, 937 (2009)
- [16] M. Bakshi, B. Singh, A. Singh, and S. Singh, J. Pharm. Biomed. Anal., 26, 891 (2001)
- [17] ICH, Stability Testing of New Drug Substances and Products (Q1AR). International Conference on Harmonization, IFPMA, Geneva, 2000
- [18] M. Bakshi, B. Singh, A. Singh, and S. Singh, J. Pharm. Biomed. Anal., 28, 1011 (2002)
- [19] R. Sehrawat, M. Maithani, R. Singh, Chromatographia, 72, 1 (2010)
- [20] J. Cielecka-Piontek, A. Lunzer, and A. Jelińska, Cent. Eur. J. Chem., 9, 35 (2011)
- [21] J. Cielecka-Piontek and A. Jelińska, React. Kinet. Mech. Cat., 102, 37 (2011)
- [22] J. Cielecka-Piontek and A. Jelińska, Spectrochim. Acta Mol. Biomol. Spectros., 77, 554 (2010)
- [23] J. Cielecka-Piontek, K. Michalska, P. Zalewski, A. Jelińska, Cur. Pharm. Anal., 7, 213 (2011)
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-ea9a9c12-3464-4731-b544-aaeadc582eb1